Press Release updated: Jun 17, 2019 16:44 EDT

NEW YORK, June 17, 2019 – ​​​​​​​​​​​Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Dr. Roger Frechette to its Executive Team as Director of Operations & Business Development.

Dr. Frechette has 30 years of experience as a scientist, business leader and entrepreneur in the Bio-Pharmaceutical industry. He is the Co-Founder and Principal of New England PharmAssociates (NEPA), a life science operations, strategy and business development consultancy. Prior to NEPA, he co-founded MaxThera, a biopharmaceutical company developing novel antibacterial drugs. MaxThera was acquired by Australian company Biota Holdings. Previously, he was a Project Director of Paratek Pharmaceuticals, where he led discovery and early development teams for the now marketed drug Nuzyra (Omadacycline). Dr. Frechette was previously Associate Director at Ribogene and a Senior Scientist at Johnson and Johnson’s RW Johnson Pharmaceutical Research Institute. He completed a Ph.D. in Chemistry at Wesleyan University and was a NIH postdoctoral fellow at Yale University.

“We are thrilled to have Dr. Frechette joining our leadership team. His deep domain expertise and business leadership will enable Akelos to accelerate its trajectory in commercializing a novel, non-opioid drug to treat chronic and neuropathic pain,” said Dr. Steven Fox, chairman of Akelos, Inc. “The addition of Dr. Frechette is an important milestone to realizing our goals.”

Akelos Inc., is in a research collaboration with Weill Cornell Medicine to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain.

For more information, please contact:

Akelos Inc.

Dr. Steven Fox, CEO
[email protected]

About Akelos Inc.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs.

Forward-Looking Statement

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our  budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations, and market opportunity and competition.

The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Source: Akelos Inc.

Powered by WPeMatico